Mentari Therapeutics, Inc. logo

Mentari Therapeutics, Inc.(MTRI)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 4 days
PROFIT SINCE LAST BUY
-23.27% ▼
LAST CLOSE
$18.6
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MTRI

11/13/2026: MTRI (1-star) is a SELL. SELL for 4 days. Simulated Profits (-23.27%). Updated daily EoD!

Mentari Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for migraine prevention, featuring lead candidates like MT-001 and MT-002. The company's primary strength lies in its innovative approach targeting validated PACAP and CGRP pathways to address patients unresponsive to standard treatments. Its main growth opportunity rests on successful clinical advancement and potential commercialization within the lucrative neurology market. However, the company faces high risks typical of early-stage biotech, including binary clinical trial outcomes and intense competition from pharmaceutical giants. Mentari is best suited for growth-oriented investors comfortable with high volatility and clinical development risk.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers exposure to high-growth clinical-stage biotechnology innovation targeting large neurology markets.
Momentum investorStrong fit while signal remains positiveClinical catalysts and news flow can trigger sharp near-term price movements typical of clinical-stage biotech stocks.
Value investorWeak fitThe company lacks commercial earnings or traditional value-metric support at this stage of clinical development.
Dividend investorWeak fitAs a pre-revenue clinical-stage biotech, Mentari does not pay dividends.
Low-risk investorWeak fitHigh clinical development risks and share price volatility make it unsuitable for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience dramatic price swings based on trial data and market sentiment.
Valuation riskHighValuation is heavily dependent on future clinical success and pipeline potential rather than current revenue.
Competition risk (large pharmaceutical competition)HighThe migraine treatment market features entrenched, well-funded competitors with established commercial footprints.
Business qualityMediumThe company possesses promising scientific assets, but lacks the commercial-stage infrastructure of established drug makers.
Dividend incomeLow / noneNo dividends are paid or anticipated in the foreseeable future.
Execution riskHighSuccess relies entirely on the smooth execution of complex preclinical and clinical development programs.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.08B USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 17.8K shares
Beta -
52 Weeks Range 5.75 - 23.30
Updated Date 11/14/2026
52 Weeks Range 5.75 - 23.30
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -69.95%
Avg. Invested days 15
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MTRI receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics.

Company Fundamentals

★★★★★
MTRI has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and soft ownership. Growth and ownership metrics are mixed: slightly negative earnings growth (+0.0%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
MTRI's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
MTRI's growth profile is soft, with the least-weak measure being revenue growth at +0.0% year over year. By comparison, while earnings growth (+0.0%, slightly negative) and free-cash-flow growth (+0.0%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.4% (soft) and 0.0% of outstanding shares are publicly tradable (soft). Insider ownership is only 0.00%, which materially reduces the ownership score.

Unit Economics (Per $1K Revenue)

★★★★★
MTRI generates approximately $0 of gross profit, $0 of operating income, and $0 of free cash flow for every $1,000 of revenue. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 21.00%

Quantitative Style Profile

★★★★★
MTRI has a relatively low-volatility profile. No single quantitative factor dominates as a drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic R&D and Pipeline DevelopmentFuture commercialization rights, potential milestone payments, and product sales stemming from migraine therapies like MT-001 and MT-002.The company does not make money yet; future returns depend on successfully developing and commercializing drugs.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.05B
Price to Sales(TTM) -
Enterprise Value 1.05B
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 58.30M
Shares Floating -
Shares Outstanding 58.30M
Shares Floating -
Percent Insiders -
Percent Institutions 1.38

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.